Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
5,856
datasets available to search
ShareScore release 0.9.0
Dataset results
5,856 results for “B cells”
ATM deficiency in the absence of T cells promotes the development of NF-kB-dependent B cell lymphomas [aCGH]
GEO Series GSE59577. Mus musculus. 23 samples. Type: Genome variation profiling by array; Genome variation profiling by genome tiling array.
Semimethylation is a feature of Diffuse Large B-cell Lymphoma, and subgroups with poor prognosis are characterized by global hypomethylation and short telomere length
GEO Series GSE255869. Homo sapiens. 97 samples. Type: Methylation profiling by array.
Early NKT cell wave of IL-4 serves as an innate link to support initiation of B cell immunity during infection
GEO Series GSE103753. Mus musculus. 222 samples. Type: Expression profiling by high throughput sequencing.
Input data files for RSS-NET analysis of simulated GWAS summary statistics and B cell regulatory network
<p>Details of these data files are provided in https://suwonglab.github.io/rss-net/wtccc_bcell.</p> <p>Contact:<code> xiangzhu[at]psu.edu </code></p>
Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
<p>The following folders/files are part of this repository:</p> <p> </p> <ul> <li>“List of samples” excel file: contains the list of samples used in this project</li> </ul> <p> </p> <ul> <li>CD8_ANALYSIS: contains two folders: CTRLs (control samples) and TMA (DLBCL TMA sample cores in duplicate).</li> </ul> <p>Each subfolder contains the following excel files:</p> <ul> <li>ImageNumber_legend_and_counts: excel file summarizing the image number associated to each sample, total number of CD8 and number of CD8 in contact with stroma</li> <li>Info_CP_Pipeline: cell profile pipeline used for CD8 analysis</li> <li>MyExpt_CD8_objects: raw data of all CD8</li> <li>MyExpt_CD8_on_stroma: raw data of all CD8</li> </ul> <p> </p> <ul> <li>ORIGINAL_IMAGES: it contains two folders: <ul> <li>exclusion_masks: masks used to exclude areas of the tissue from the analysis</li> <li>Original_images: spillover corrected TIFF images for each channel</li> </ul> </li> </ul> <p> </p> <ul> <li>STROMAL_CELL_ANALYSIS: <ul> <li>FRCs_Network_Shape: overlay TIFF images of the stromal network shape</li> <li>PDL1_PDL2_Stromal_Masks: TIFF images of stromal cell masks for PD-L1 and PD-L2 checkpoints expression</li> <li>Stromal_Cell_Masks: TIFF images of stromal cell masks for the three main stromal subpopulations of the lymph node (BECs, LECs, FRCs)</li> </ul> </li> </ul>
Data from: Variations in HLA-B cell surface expression, half-life and extracellular antigen receptivity
The highly polymorphic human leukocyte antigen (HLA) class I molecules present peptide antigens to CD8+ T cells, inducing immunity against infections and cancers. Quality control mediated by peptide loading complex (PLC) components is expected to ensure the cell surface expression of stable peptide-HLA class I complexes. This is exemplified by HLA-B*08:01 in primary human lymphocytes, with both expression level and half-life at the high end of the measured HLA-B expression and stability hierarchies. Conversely, low expression on lymphocytes is measured for three HLA-B allotypes that bind peptides with proline at position 2, which are disfavored by the transporter associated with antigen processing. Surprisingly, these lymphocyte-specific expression and stability differences become reversed or altered in monocytes, which display larger intracellular pools of HLA class I than lymphocytes. Together, the findings indicate that allele and cell-dependent variations in antigen acquisition pathways influence HLA-B surface expression levels, half-lives and receptivity to exogenous antigens.
Bar Chart of the Analysis of the Mean Number of SCUBE3 and TGF-B Expressing Cells in the Treatment Group
<p>The following diagrams present the results of the analysis of SCUBE3 and TGF-b gene expression. These diagrams are divided into eight main groups based on sample preparation size and incubation time. These groups consist of diagrams that present the relationship between treatment groups in 1x1 cm and 2x2 cm preparations, which have 24-hour and 72-hour incubation times for SCUBE3 and TGF-b, respectively. </p>
Primary SARS-CoV-2 variant of concern infections elicit broad antibody Fc-mediated effector functions and memory B cell responses
<p><span>Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by human sera is a strong correlate of protection against symptomatic and severe Coronavirus Disease 2019 (COVID-19). The emergence of antigenically distinct SARS-CoV-2 variants of concern (VOCs) and the relatively rapid waning of serum antibody titers, however, raises questions about the sustainability of serum protection. In addition to serum neutralization, other antibody functionalities and the memory B cell (MBC) response are suggested to help maintaining this protection. In this study, we investigate the breadth of spike (S) protein-specific serum antibodies that mediate effector functions by interacting with Fc-gamma receptor IIa (<span>FcγRIIa) and FcγRIIIa,</span> and of the receptor binding domain (RBD)-specific MBCs, following a primary SARS-CoV-2 infection with the D614G, Alpha, Beta, Gamma, Delta, Omicron BA.1 or BA.2 variant. Irrespectively of the variant causing the infection, the breadth of S protein-specific serum antibodies that interact with <span>FcγRIIa and FcγRIIIa and the RBD-specific MBC responses </span>exceeded the breadth of serum neutralization, although the Alpha-induced B cell response seemed more strain-specific<span>. Between VOC groups, both quantitative and qualitative differences in the immune responses were observed, suggesting differences in immunogenicity. Overall</span>, this study contributes to the understanding of protective humoral and B cell responses in the light of emerging antigenically distinct VOCs, and highlights the need to study the immune system beyond serum neutralization <span>to gain a better understanding of the protection against emerging variants. </span></span></p>
Bioinformatical workflow and results for Group B Streptococcal transcriptome when interacting with brain endothelial cells
<p>Bioinformatical workflow and results for the manuscript Group B Streptococcal transcriptome when interacting with brain endothelial cells </p>
A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
ClinicalTrials.gov study NCT03758989. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Does Abatacept Induce Regulatory B Cells in Patients With Rheumatoid Arthritis
ClinicalTrials.gov study NCT02885818. IPD Sharing: NO. Countries: 1. Publications: 0.
Mechanism of IL-10 Pathway-mediated Regulatory B Cell Dysfunction in Osteoarthritis
ClinicalTrials.gov study NCT06227195. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma
ClinicalTrials.gov study NCT04842877. IPD Sharing: NO. Countries: 2. Publications: 0.
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies
ClinicalTrials.gov study NCT01760226. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Transcriptomics Signature of Anti Vaccinia Memory B Cells
ClinicalTrials.gov study NCT02556489. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant
ClinicalTrials.gov study NCT05526313. IPD Sharing: NO. Countries: 1. Publications: 0.
The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancie
ClinicalTrials.gov study NCT07020260. IPD Sharing: NO. Countries: 1. Publications: 0.
The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP
ClinicalTrials.gov study NCT00440583. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
ClinicalTrials.gov study NCT05820841. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma
ClinicalTrials.gov study NCT03688152. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.